Invo BioScience (INVO)
(Delayed Data from NSDQ)
$1.17 USD
-0.13 (-10.00%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $1.07 -0.10 (-8.55%) 7:52 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Invo BioScience Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 0 | 0 | 6 | 10 | 1 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 0 | 0 | 0 | 0 |
Total Current Assets | 1 | 1 | 6 | 11 | 2 |
Net Property & Equipment | 1 | 0 | 1 | 0 | 0 |
Investments & Advances | 3 | 1 | 1 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 10 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 21 | 4 | 10 | 11 | 2 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 2 | 1 | 0 | 1 | 0 |
Accounts Payable | 2 | 1 | 0 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 1 | 1 | 1 | 1 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3 | 0 | 0 | 1 | 1 |
Total Current Liabilities | 8 | 3 | 1 | 2 | 2 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 3 | 4 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 1 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 20 | 5 | 3 | 5 | 6 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 6 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 53 | 49 | 46 | 38 | 20 |
Retained Earnings | -58 | -50 | -39 | -32 | -24 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 1 | -1 | 7 | 6 | -4 |
Total Liabilities & Shareholder's Equity | 21 | 4 | 10 | 11 | 2 |
Total Common Equity | -5 | -1 | 7 | 6 | -4 |
Shares Outstanding | 2.40 | 0.60 | 0.50 | 0.40 | 0.20 |
Book Value Per Share | -2.13 | -1.63 | 14.62 | 14.35 | -18.55 |
Fiscal Year End for Invo BioScience Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 0 | 1 | -99,999 | 2 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | NA | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 1 | 0 | 0 | 0 |
Total Current Assets | NA | 1 | 2 | 1 | 3 |
Net Property & Equipment | NA | 1 | 1 | 1 | 0 |
Investments & Advances | NA | 3 | 1 | 1 | 1 |
Other Non-Current Assets | NA | 0 | 0 | NA | 0 |
Deferred Charges | NA | 0 | 0 | NA | 0 |
Intangibles | NA | 10 | 10 | NA | 0 |
Deposits & Other Assets | NA | 0 | 0 | NA | 0 |
Total Assets | NA | 21 | 19 | 7 | 6 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 2 | 2 | 1 | 1 |
Accounts Payable | NA | 2 | 2 | 2 | 2 |
Current Portion Long-Term Debt | NA | 0 | 0 | NA | 0 |
Current Portion Capital Leases | NA | 0 | 0 | NA | 0 |
Accrued Expenses | NA | 1 | 1 | 1 | 1 |
Income Taxes Payable | NA | 0 | 0 | NA | 0 |
Other Current Liabilities | NA | 3 | 0 | 0 | 0 |
Total Current Liabilities | NA | 8 | 5 | 4 | 4 |
Mortgages | NA | 0 | 0 | NA | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | NA | 0 |
Long-Term Debt | NA | 1 | 1 | NA | 0 |
Non-Current Capital Leases | NA | 0 | 0 | NA | 0 |
Other Non-Current Liabilities | NA | 8 | NA | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | NA | 0 |
Total Liabilities | NA | 20 | 19 | 8 | 6 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 6 | 0 | NA | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 53 | 56 | 53 | 52 |
Retained Earnings | NA | -58 | -56 | -55 | -52 |
Other Equity | NA | 0 | 0 | NA | 0 |
Treasury Stock | NA | 0 | 0 | NA | 0 |
Total Shareholder's Equity | NA | 1 | 0 | -2 | 0 |
Total Liabilities & Shareholder's Equity | NA | 21 | 19 | 7 | 6 |
Total Common Equity | 0 | -5 | 0 | 99,997 | 0 |
Shares Outstanding | 2.70 | 2.40 | 2.40 | 0.80 | 0.70 |
Book Value Per Share | 0.00 | -2.13 | 0.15 | 124,996.61 | 0.13 |